27127
document
Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease : subanalysis of a parallel group , open-label , dose-escalation study . OBJECTIVE Rotigotine ( Neupro ) is formulated as a transdermal delivery system designed to provide a selective , non-ergot D3/D2/D1 agonist to the systemic blood flow over a 24-hour period . In clinical trials , patches were applied once daily and uptitrated to the individual effective dose in increments of 2 mg/24 h every week . The aim of this analysis was to determine the safety of a more rapid titration of rotigotine by assessing the tolerability of escalating transdermal doses of rotigotine given in 2 different titration schemes . METHODS We analyzed the safety of rotigotine in 2 groups of patients with advanced stage Parkinson Disease . The starting dose of 4 mg/24 h was increased every week by 2 mg/24 h in the slow-titration group and 4 mg/24 h in the fast-titration group . The primary focus of this subanalysis was the separate tolerability of rotigotine in each randomized treatment arm , during the dose-escalation period . However , the 2 titration schemes were also compared with each other . RESULTS The dose of first reported nausea and/or vomiting was 8 mg/24 h for the fast-titration group and 4 mg/ 24 h for the slow-titration group . There were no remarkable differences concerning the side-effect profile between the 2 different titration schemes . CONCLUSIONS The fast-titration regimen had a similar adverse event profile to slower titration , and allowed rotigotine to be introduced quickly . This subanalysis suggests that rotigotine may be uptitrated more rapidly .
27128
Intervention_Pharmacological
Rotigotine transdermal patch
27129
Intervention_Pharmacological
Rotigotine ( Neupro )
27130
Intervention_Pharmacological
patches
27131
Intervention_Pharmacological
rotigotine
27132
Intervention_Pharmacological
rotigotine
27133
Intervention_Pharmacological
rotigotine
27134
Intervention_Pharmacological
rotigotine
27135
Intervention_Pharmacological
rotigotine
27136
Intervention_Pharmacological
rotigotine
27137
Outcome_Other
safety
27138
Outcome_Other
safety
27139
Outcome_Other
tolerability of rotigotine
27140
Outcome_Adverse-effects
nausea and/or vomiting
27141
Outcome_Adverse-effects
side-effect profile
27142
Outcome_Adverse-effects
adverse event profile
27143
Participant_Condition
advanced-stage idiopathic Parkinson disease
27144
Participant_Condition
advanced stage Parkinson Disease